Cutera (NASDAQ:CUTR) Rating Reiterated by Stephens

Cutera (NASDAQ:CUTR)‘s stock had its “overweight” rating reiterated by investment analysts at Stephens in a research report issued on Friday, Benzinga reports. They currently have a $10.00 price target on the medical device company’s stock.

Separately, William Blair upgraded shares of Cutera from an “underperform” rating to a “market perform” rating in a research note on Friday. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $14.75.

Cutera Price Performance

NASDAQ:CUTR opened at $1.60 on Friday. The firm’s 50-day moving average price is $2.53 and its 200-day moving average price is $3.57. The company has a market capitalization of $31.90 million, a PE ratio of -0.22 and a beta of 1.70. Cutera has a 1-year low of $1.38 and a 1-year high of $27.39.

Cutera (NASDAQ:CUTR) last released its earnings results on Tuesday, March 5th. The medical device company reported ($2.22) earnings per share for the quarter. The firm had revenue of $46.48 million for the quarter. Equities analysts anticipate that Cutera will post -3.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Cutera

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. lifted its stake in Cutera by 2.0% during the 2nd quarter. Prudential Financial Inc. now owns 17,625 shares of the medical device company’s stock valued at $708,000 after acquiring an additional 340 shares during the period. Fuller & Thaler Asset Management Inc. lifted its stake in Cutera by 0.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 79,800 shares of the medical device company’s stock valued at $5,506,000 after acquiring an additional 425 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Cutera by 10.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,619 shares of the medical device company’s stock valued at $173,000 after acquiring an additional 434 shares during the period. Captrust Financial Advisors lifted its stake in Cutera by 592.2% during the 1st quarter. Captrust Financial Advisors now owns 533 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 456 shares during the period. Finally, Almanack Investment Partners LLC. bought a new position in Cutera during the 3rd quarter valued at about $25,000.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.